Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous syst... Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous system disorders. The company focuses on conditions with limited treatment options, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Axsome's approach includes fixed-dose combinations and reformulations designed to deliver differentiated therapeutic solutions. The company maintains a pipeline of clinical-stage CNS therapies addressing significant and growing markets. Founded in 2012 and headquartered in New York, New York, Axsome operates as a single business segment dedicated to developing and delivering innovative treatments for patients with underserved CNS conditions. The company has transitioned to commercializing its marketed products while advancing its pipeline of differentiated therapeutic candidates.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Axsome Therapeutics is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Axsome Therapeutics is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Axsome Therapeutics's data?

Start your 30-day free trial to request a data review for Axsome Therapeutics.

Start Free Trial

Legal Center Contact Us

Axsome Therapeutics Inc

Axsome Therapeutics is not subject to EU Taxonomy reporting

Account Restricted